Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study
February 02, 2021 08:30 ET
|
Cassava Sciences, Inc.
- Patients’ Cognition Improved 1.6 Points on ADAS-Cog11 -- Patients’ Behavior Improved 1.3 Points on NPI - - Improvements Maintained at 6 Months - - Results Support Advancing Simufilam into Phase 3...
Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer
January 04, 2021 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of James...
USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’
November 27, 2020 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 27, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN)...
Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock
November 13, 2020 09:08 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Announces Proposed Public Offering of Common Stock
November 12, 2020 16:48 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease,...
Cassava Sciences Reports Third Quarter 2020 Financial Results
November 09, 2020 08:15 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today reported financial results for...
Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’s Disease
November 04, 2020 08:15 ET
|
Cassava Sciences, Inc.
Alzheimer’s Patients Treated with Sumifilam Showed a Statistically Significant (p<0.001) Treatment Benefit on HMGB1, a Protein that Triggers Neuroinflammation and Loss of Neurons Alzheimer’s...
Cassava Sciences’ Phase 2b Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2020
September 30, 2020 08:30 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, today announced that clinical...
Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Sumifilam in Patients with Alzheimer’s Disease
September 14, 2020 07:15 ET
|
Cassava Sciences, Inc.
Alzheimer’s Patients in Drug Groups Showed Statistically Significant Improvements in Biomarkers of Disease Compared to Placebo Group (P<0.05) Alzheimer’s Patients in Drug Groups Showed...
Cassava Sciences to Hold Conference Call on Monday, September 14, 2020 at 8:30 am ET
September 11, 2020 16:01 ET
|
Cassava Sciences, Inc.
AUSTIN, Texas, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a...